The Phase 2 dose-finding trial (N=338), published in the New England Journal of Medicine in 2023 (DOI: 10.1056/NEJMoa2301972), randomized participants with obesity (BMI 30-50) to retatrutide at doses ranging from 0.5mg to 12mg weekly or placebo over 48 weeks
Contrave: Nausea, constipation, headache, insomnia Increased blood pressure and heart rate Other effects: anxiety, dizziness, dry mouth, tremors, risk of seizures in susceptible individuals Serious risks: liver problems, severe allergic reactions, neuropsychiatric events, including mood changes or suicidal thoughts Wegovy: Gastrointestinal issues: nausea, vomiting, diarrhea, constipation, abdominal pain Other effects: fatigue, headache, dizziness (especially during dose escalation) Serious risks: pancreatitis, gallbladder disease, thyroid tumors in high-risk patients, increased heart rate Important: Neither medication is a cure for obesity
In a combination protocol, some researchers theorize that starting at a lower dose (1mg daily) and assessing tolerance before escalating to the full 2mg might reduce the risk of compounding side effects with retatrutide
Label your vial immediately after reconstitution
